- Investing Ideas
- /
- U.S. Pharmaceuticals & Biotech High Growth Potential Companies
U.S. Pharmaceuticals & Biotech High Growth Potential Companies
UPDATED Nov 26, 2023
Companies with a Future performance score of at least 3, ordered by Future performance score.
167 companies
| Company | Last Price | 7D Return | 1Y Return | Market Cap | Analysts Target | Valuation | Growth | Div Yield | ||
|---|---|---|---|---|---|---|---|---|---|---|
| RIGLRigel Pharmaceuticals | US$1.04 | 11.1% | 46.3% | US$181.3m | US$4.04 | PS1.4x | E71.7% | n/a | ||
| SNDLSNDL | US$1.50 | -2.0% | -40.5% | US$390.7m | US$3.64 | PB0.4x | E73.3% | n/a | ||
| SHCSotera Health | US$13.90 | -0.2% | 70.6% | US$3.9b | US$16.42 | PS4x | E97.3% | n/a | ||
| TXG10x Genomics | US$43.36 | -0.1% | 24.9% | US$5.1b | US$54.83 | PS8.7x | E57.1% | n/a | ||
| BLFSBioLife Solutions | US$14.08 | 5.0% | -31.8% | US$634.3m | US$22.14 | PS4.1x | E76.2% | n/a | ||
| PCRXPacira BioSciences | US$26.91 | -2.7% | -45.0% | US$1.2b | US$49.11 | PE179x | E37.2% | n/a | ||
| OGNOrganon | US$11.36 | 1.5% | -53.9% | US$2.9b | US$20.33 | PE5x | E24.5% | 9.9% | ||
| ILMNIllumina | US$98.34 | 0.7% | -54.7% | US$15.6b | US$153.35 | PS3.5x | E80.3% | n/a | ||
| ACHVAchieve Life Sciences | US$5.44 | -1.3% | 89.5% | US$115.1m | US$28.00 | PB28.5x | E68.6% | n/a | ||
| CINGCingulate | US$0.36 | 4.5% | -64.3% | US$6.7m | US$5.69 | PE-0.3x | E51.0% | n/a | ||
| ATOSAtossa Therapeutics | US$0.79 | 6.7% | 2.5% | US$99.0m | US$4.75 | PB1x | E73.6% | n/a | ||
| SLNOSoleno Therapeutics | US$28.87 | 3.3% | 2,676.0% | US$880.5m | US$45.50 | PB37.9x | E74.4% | n/a | ||
| MEDPMedpace Holdings | US$277.02 | 0.4% | 30.3% | US$8.5b | US$278.60 | PE31.1x | E14.6% | n/a | ||
| RCELAVITA Medical | US$10.73 | -14.4% | 60.1% | US$274.2m | US$24.52 | PS6x | E47.8% | n/a | ||
| AVTRAvantor | US$20.32 | 4.5% | -3.7% | US$13.7b | US$23.25 | PE37.7x | E29.9% | n/a | ||
| HZNPHorizon Therapeutics | US$116.30 | 0.06% | 82.8% | US$26.6b | US$116.50 | PE60.8x | E16.4% | n/a | ||
| ABBVAbbVie | US$138.67 | 0.3% | -12.5% | US$244.8b | US$167.35 | PE37.8x | E16.9% | 4.5% | ||
| SUPNSupernus Pharmaceuticals | US$27.83 | 1.9% | -21.8% | US$1.5b | US$41.00 | PE59.3x | E65.5% | n/a | ||
| PAHCPhibro Animal Health | US$10.54 | 0.7% | -12.9% | US$426.9m | US$12.50 | PE20.6x | E31.9% | 4.6% | ||
| AZTAAzenta | US$57.66 | 2.9% | -0.2% | US$3.2b | US$58.50 | PS4.9x | E48.8% | 0% | ||
| BPTHBio-Path Holdings | US$0.48 | -4.8% | -67.8% | US$6.0m | US$12.00 | PB2.4x | E64.8% | n/a | ||
| TENXTenax Therapeutics | US$0.36 | 0.8% | -88.0% | US$8.7m | US$5.50 | PB0.8x | E68.3% | n/a | ||
| ELANElanco Animal Health | US$11.94 | 0.5% | -1.7% | US$5.9b | US$13.33 | PS1.3x | E96.5% | n/a | ||
| BIOBio-Rad Laboratories | US$311.19 | 4.0% | -23.0% | US$9.0b | US$444.60 | PS3.3x | E57.6% | n/a |